SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is trending due to its binding partnership with crypto.com/us to launch an event-based prediction markets product in the United States. This news is driving immense excitement and high volatility, with the community speculating on the low-float stock's potential to capitalize on a multi-trillion dollar market. Traders are actively discussing the possibility of a substantial short squeeze and comparing ROLR to previous explosive runs within the online gambling and crypto sectors.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investor interest intensifies around the critical role of photonics and optical interconnects in next-generation AI and data center infrastructure, following recent industry discussions on co-packaged optics. The community is highly optimistic about POET's patented Optical Interposer technology, viewing it as a game-changer for efficient, high-volume production of optical engines that address bottlenecks in AI computing. Many anticipate imminent news regarding substantial production orders or partnerships with major industry players, despite ongoing market dynamics influenced by upcoming options expiry and perceived price manipulation.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark (CLSK) is trending due to its notable market momentum, with the community observing its strong performance relative to peers like IREN. A primary talking point among investors revolves around the company's ambitious growth plans and potential share dilution concerns to finance these expansions, despite an overarching bullish sentiment.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is experiencing significant volatility, marked by a notable price decline occurring despite recent bullish analyst upgrades that highlight its AI-powered AXON platform and expanding e-commerce advertising initiatives. The community is sharply divided, with many actively buying the dip and attributing the downturn to market manipulation or broader tech sector weakness, while others express concerns about overvaluation and potential further correction. The stock's characteristic swings keep traders engaged, debating its strategic position in the evolving ad-tech landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is generating significant market discussion amid the J.P. Morgan Healthcare Conference, driven by recent advancements in its obesity drug pipeline and the appointment of a Chief Commercial Officer. The community is sharply divided, with many anticipating a major partnership or acquisition given a peer CEO's remarks on substantial M&A spending, while others express skepticism over recent stock performance and the company's presentation style.

New Century Logistics (BVI) Ltd. is a holding company, which is doing business through its subsidiaries, providing air and ocean export and import freight forwarding & logistics services. It offers cargo space, cargo pick up, off-airport air cargo security screening, palletization, preparation of shipping documentation, arrangement of customs clearance to cargo handling at ports and other related services. The company was founded on April 24, 2019 and is headquartered in Hong Kong.

New Century Logistics (BVI) Ltd.

New Century Logistics

New Century Logistics (NCEW) is gaining significant attention following its strategic acquisition announcement in Asia and partnerships for innovative drone-based last-mile delivery. The community is actively discussing its extremely low share float and drawing comparisons to other "Hong Kong low float" stocks that have recently experienced substantial, volatile runs. This focus, coupled with chatter about its high short interest, positions NCEW as a speculative play within the logistics sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to robust preliminary revenue guidance for its flagship MS drug Briumvi, which is surpassing expectations for 2025 and 2026 and positioning it for potential blockbuster status. The community is actively discussing Briumvi's best-in-class profile and market share expansion, especially amidst a competitor's recent regulatory setback, while also expressing frustration over the stock's current valuation and perceived manipulation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to significant high-grade rare earth element drilling results from its Tanbreez project, which confirm strategic metals crucial for Western supply chains. The market is also heavily anticipating outcomes from high-level meetings between U.S., Danish, and Greenlandic officials regarding potential U.S. involvement in Greenland's critical mineral resources. This confluence of positive exploration news and strategic geopolitical interest is driving widespread community discussion and strong conviction among investors despite recent volatility.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity is trending amid a wave of analyst upgrades, citing its strengthening mobile advertising platform and the growth potential of new commerce tools within the broader real-time 3D development space. The community is actively discussing a potential breakout beyond previous resistance levels, with many viewing recent dips as buying opportunities while others remain cautious given historical volatility. Optimism is fueled by the performance of its Vector AI platform and strategic partnerships, indicating confidence in its long-term trajectory across gaming, digital twins, and AI applications.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending due to a convergence of compelling clinical advancements and anticipated corporate catalysts. The community is actively discussing strong pancreatic cancer data, a recent FDA filing for recurrent skin cancer, and awaiting Japanese regulatory approval, all contributing to significant market momentum. Investors are keenly focused on the company's presentation at a major healthcare conference this week, alongside widespread anticipation of increased institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +4.74% and +2.80%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates

Indivior (INDV) delivered earnings and revenue surprises of +96.15% and +22.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Shares of CASI Pharmaceuticals, Inc. (CASI) traded 5% higher on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6899273834937655">announced</a> that it has received a buyout proposal valuing the company’s operations in China at $20 million.The proposal, dated April 2, was put forth by company CEO Wei-Wu He and covers the company’s entire business operations in China and all license-in, distribution, and related rights in Asia, excluding Japan, related to certain pipeline products.CASI said the proposal updates the preliminary non-binding proposal letter submitted by He to the company on June 21, 2024.The company said that its special committee of the board of directors will evaluate the proposed transaction. However, no decisions have been made regarding the proposal letter or any alternative strategic option the company may pursue. &nbsp;The company added that there is no assurance that any definitive agreement relating to the proposal letter will be entered between the company and its CEO.On Stocktwits, retail sentiment about CASI Pharmaceuticals dipped slightly within the ‘extremely bullish’ territory (94/100), accompanied by a slight drop in message volume over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_1_58_58_PM_png_20cfaa728f.webp" alt="CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits" width="654" height="149"><figcaption>CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> Late last month, CASI Pharma reported full-year 2024 revenue of $28.5 million, a decrease of 16% compared to 2023. The company noted that it was impacted by intensified competition and increased pricing pressure during the year.Net loss for the year came in at $39.3 million, higher than the $26.3 million reported in 2023.The company added that it had cash and cash equivalents of $13.5 million as of the end of 2024, less than the $29.1 million as of 2023-end.<a href="https://stocktwits.com/symbol/CASI">CASI shares</a> are down by over 25% this year and over 30% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gm-marks-marginal-sales-growth-in-china-in-q1/chf7IpJRbeZ">GM Marks Marginal Sales Growth In China In Q1: But Retail Continues To Stay Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

The company said that its special committee of the board of directors will evaluate the proposed transaction.

Equity

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

CASI Pharmaceuticals Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$0.9616
Prev Close	$1.04
Open	$1.06
Dividend Yield	0.00%
50-Day Moving Average	$1.04
Beta	0.46
Avg. Volume	36,242.95
PE Ratio	-0.33

52-Week High	$3.09
52-Week Low	$0.75
Market Capitalization	$16.54M
EPS (Annual)	-$2.56
Price to Book	-0.63
Revenue Per Employee	$122,476.40
Enterprise Value/EBITDA	N/A

CASI
CASI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CASI News

CASICASI Pharmaceuticals Inc